A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of ACE-083 in Patients With Facioscapulohumeral Muscular Dystrophy

Trial Profile

A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of ACE-083 in Patients With Facioscapulohumeral Muscular Dystrophy

Recruiting
Phase of Trial: Phase II

Latest Information Update: 08 Jan 2018

At a glance

  • Drugs ACE 083 (Primary)
  • Indications Facioscapulohumeral muscular dystrophy
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Acceleron Pharma
  • Most Recent Events

    • 08 Jan 2018 According to an Acceleron media release, the company plans to initiate Part 2 in Q2 2018.
    • 08 Jan 2018 Results for the first two cohorts Part 1 of this trial (n=23) published in an Acceleron media release Media Release
    • 07 Nov 2017 According to an Acceleron media release, Phase 2 results for cohort 1 in Part 1 are expected in January 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top